[1] WARDAK S. Human papillomavirus (HPV) and cervical cancer[J]. Med Dosw Mikrobiol, 2016, 68(1):73-84.
[2] GUO F J, COFIE L E, BERENSON A B. Cervical cancer incidence in young US females after human papillomavirus vaccine introduction[J]. Am J Prev Med, 2018, 55(2):197-204.
[3] HE Y Y, YU H, ROZEBOOM L, et al. LAG-3 protein expression in non-small cell lung cancer and its relationship with PD-1/PD-L1 and tumor-infiltrating lymphocytes[J]. J Thorac Oncol, 2017, 12(5):814-823.
[4] KIM J M, CHEN D S. Immune escape to PD-L1/PD-1 blockade:seven steps to success (or failure)[J]. Ann Oncol, 2016, 27(8):1492-1504.
[5] ISHIDA Y, AGATA Y, SHIBAHARA K, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death[J]. EMBO J, 1992, 11(11):3887-3895.
[6] SUN H Y, SUN C, XIAO W H. Expression regulation of co-inhibitory molecules on human natural killer cells in response to cytokine stimulations[J]. Cytokine, 2014, 65(1):33-41.
[7] MAMALIS A, GARCHA M, JAGDEO J. Targeting the PD-1 pathway:a promising future for the treatment of melanoma[J]. Arch Dermatol Res, 2014, 306(6):511-519.
[8] ZAK K M, KITEL R, PRZETOCKA S, et al. Structure of the complex of human programmed death 1, PD-1, and its ligand PD-L1[J]. Structure, 2015, 23(12):2341-2348.
[9] SHEN X, ZHAO B. Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer:meta-analysis[J]. BMJ, 2018, 362:k3529.
[10] MARZEC M, ZHANG Q, GORADIA A, et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274(PD-L1, B7-H1)[J]. Proc Natl Acad Sci U S A, 2008, 105(52):20852-20857.
[11] QIN B D, JIAO X D, ZANG Y S. Tumor mutation burden to tumor burden ratio and prediction of clinical benefit of anti-PD-1/PD-L1 immunotherapy[J]. Med Hypotheses, 2018, 116:111-113.
[12] CHEN J, JIANG C C, JIN L, et al. Regulation of PD-L1:a novel role of pro-survival signalling in cancer[J]. Ann Oncol, 2016, 27(3):409-416.
[13] BOUSSIOTIS V A. Molecular and biochemical aspects of the PD-1 checkpoint pathway[J]. N Engl J Med, 2016, 375(18):1767-1778.
[14] SUNSHINE J, TAUBE J M. PD-1/PD-L1 inhibitors[J]. Curr Opin Pharmacol, 2015, 23:32-38.
[15] KATO S, GOODMAN A, WALAVALKAR V, et al. Hyperprogressors after immunotherapy:analysis of genomic alterations associated with accelerated growth rate[J]. Clin Cancer Res, 2017, 23(15):4242-4250.
[16] CHANG H N, LIU B Y, QI Y K, et al. Blocking of the PD-1/PD-L1 interaction by a D-peptide antagonist for cancer immunotherapy[J]. Angew Chem Int Ed Engl, 2015, 54(40):11760-11764.
[17] LI C L, ZHANG N P, ZHOU J D, et al. Peptide blocking of PD-1/PD-L1 interaction for cancer immunotherapy[J]. Cancer Immunol Res, 2018, 6(2):178-188.
[18] 刘大纯, 王晓霜. 腹腔镜手术治疗宫颈癌的临床效果及对生存质量的影响[J]. 基因组学与应用生物学, 2018, 37(2):596-603.
[19] 邓丽霞, 刘鑫鑫, 陈斌, 等. 三维腔内放疗在宫颈癌ⅠB1期、ⅡA1期病灶直径3~4 cm患者术前治疗中的应用效果[J]. 中国医药导报, 2018, 15(3):102-106.
[20] SAGLAM O, CONEJO-GARCIA J. PD-1/PD-L1 immune checkpoint inhibitors in advanced cervical cancer[J]. Integr Cancer Sci Therap, 2018, 5(2):1-4.
[21] HEEREN A M, PUNT S, BLEEKER M C, et al. Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix[J]. Mod Pathol, 2016, 29(7):753-763.
[22] MENG Y, LIANG H Y, HU J G, et al. PD-L1 expression correlates with tumor infiltrating lymphocytes and response to neoadjuvant chemotherapy in cervical cancer[J]. J Cancer, 2018, 9(16):2938-2945.
[23] YANG W, SONG Y, LU Y L, et al. Increased expression of programmed death (PD)-1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk human papillomavirus-related cervical intraepithelial neoplasia[J]. Immunology, 2013, 139(4):513-522.
[24] LIU Z D, ZHOU H, WANG W J, et al. A novel dendritic cell targeting HPV16 E7 synthetic vaccine in combination with PD-L1 blockade elicits therapeutic antitumor immunity in mice[J]. Oncoimmunology, 2016, 5(6):e1147641. DOI:10.1080/2162402X.2016.1147641.
[25] MOEINI S, SAEIDI M, FOTOUHI F, et al. Synergistic effect of programmed cell death protein 1 blockade and secondary lymphoid tissue chemokine in the induction of anti-tumor immunity by a therapeutic cancer vaccine[J]. Arch Virol, 2017, 162(2):333-346.
[26] 魏洁, 寇蓬, 廉阳秧, 等. 阻断PD-L1/PD-1途径增强顺铂化疗效果的实验研究[J]. 实用医学杂志, 2016, 32(1):47-50.
[27] FRENEL J S, LE TOURNEAU C, O'NEIL B, et al. Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer:results from the phase ib KEYNOTE-028 trial[J]. J Clin Oncol, 2017, 35(36):4035-4041.
[28] BOUSSIOS S, SERAJ E, ZARKAVELIS G, et al. Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens:Where do we stand? A literature review[J]. Crit Rev Oncol Hematol, 2016, 108:164-174.
[29] GIBNEY G T, WEINER L M, ATKINS M B. Predictive biomarkers for checkpoint inhibitor-based immunotherapy[J]. Lancet Oncol, 2016, 17(12):e542-e551.
[30] 赵碧霞, 谢文柳, 蒋佩佩, 等. 发展中国家接种人乳头瘤病毒疫苗的影响因素[J]. 现代生物医学进展, 2015, 15(20):3971-3974. |
